Skip to main content
OpenTrials
Completed

NCT Number: NCT01555619

Quadripolar Pacing Post Approval Study

The purpose of this post-approval study is to evaluate the acute and chronic performance of a Quadripolar CRT-D device system in a patient population indicated for cardiac resynchronization therapy (CRT).

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

Cardiology, P.C., Birmingham, Alabama, United States

Loading trial locations.

About this study

Quad PAS is a multi-center, post-approval study. Patients who meet inclusion/exclusion criteria will have an attempted implant of a Quadripolar CRT-D device system (device and left ventricular (LV) lead). Patients who have an unsuccessful implant will be followed for 30 days for any adverse events and then withdrawn from the study, or may have an implant reattempted if the physician chooses to do so. Patients enrolled in the study will be followed at 6 months, and every 6 months thereafter, for 60 months of follow up (5 years). After patients complete 60 months of follow-up, their participation in the study will be terminated.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Approved indication per current American College of Cardiology/American Heart Association/Heart Rhythm Society guidelines for implantation of a CRT-D system for treatment of heart failure or life threatening ventricular tachyarrhythmia(s).
  • Participated in the Promote® Q CRT-D and Quartet™ Left Ventricular Heart Lead Study (Investigational Device Exemption (IDE) study), or are receiving a new Quadripolar CRT-D device system implant or are undergoing an upgrade from an existing implantable cardioverter-defibrillator or pacemaker implant with no prior LV lead placement.
  • Have the ability to provide informed consent for study participation and be willing and able to comply with the prescribed follow-up tests and schedule of evaluations

Exclusion criteria

  • Have a hypersensitivity to a single 1.0mg dose of dexamethasone sodium phosphate
  • Have a life expectancy of less than 5 years due to any condition
  • Be less than 18 years of age

Treatment and study plan

CRT-D System

Device

Implantation of a CRT-D System

Other names: CRT-D and LV pacing lead

Primary outcomes

  1. Complication free survival rate related to the CRT-D system

    Time frame: 5 years

    Complication free survival rate through 5 years for complications related to the CRT-D system

  2. Complication free survival rate related to the LV lead

    Time frame: 5 years

    Complication free survival rate at 5 years for complications related to the LV lead

  3. Mean programmed LV lead pacing capture threshold

    Time frame: 5 years

    Mean programmed LV lead pacing capture threshold at 5 years

Sponsors and collaborators

Lead sponsor

Abbott Medical Devices

Industry

Registry information

Acronym: Quad PAS

Important dates

Study start
2012
Primary completion
2019
Study completion
2019
First posted
Mar 15, 2012
Registry last updated
Apr 16, 2019

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.